{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:04Z","timestamp":1791404224254,"version":"4.3.3"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI007531"],"award-info":[{"award-number":["T32 AI007531"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transformative changes in care for people with cystic fibrosis (CF; pwCF) have occurred, including most recently, the widespread use of CF transmembrane regulator modulator therapy. These novel therapies improve lung function, decrease pulmonary exacerbations, increase life expectancy, and improve quality of life. Changes in the CF population have also occurred. There are now more adults than children living with CF. A growing proportion of pwCF are black and\/or Hispanic, many of whom are ineligible for modulator therapy due to their CF transmembrane regulator mutations, which may further exacerbate disparities in healthcare. Management of pulmonary exacerbations\u2014including shared decision making between pwCF and providers, the limitations of antimicrobial susceptibility testing to predict treatment response, and the role of antimicrobial stewardship\u2014is increasingly recognized by the CF community. Collaborations among infectious diseases specialists, antimicrobial stewards, CF care teams, and clinical microbiology laboratories are increasingly needed to optimize these newer care paradigms.<\/jats:p>","DOI":"10.1093\/cid\/ciaf009","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:00:37Z","timestamp":1749052837000},"page":"e65-e77","source":"Crossref","is-referenced-by-count":1,"title":["State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-8451","authenticated-orcid":false,"given":"Lisa","family":"Saiman","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases and Department of Infection Prevention and Control, Columbia University Irving Medical Center\/New York\u2013Presbyterian Hospital , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-6372","authenticated-orcid":false,"given":"Laurie","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Pulmonology, Columbia University Irving Medical Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-4112","authenticated-orcid":false,"given":"A Whitney","family":"Brown","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation , Bethesda, Maryland ,","place":["USA"]},{"name":"Inova Advanced Lung Disease and Lung Transplant Program , Falls Church, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025060412003453500_ciaf009-B1","volume-title":"Cystic Fibrosis Foundation Patient Registry: 2022 annual data report","author":"Cystic Fibrosis Foundation","year":"2023"},{"key":"2025060412003453500_ciaf009-B2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ijns6010018","article-title":"Newborn screening for CF across the globe\u2014where is it worthwhile?","volume":"6","author":"Scotet","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"2025060412003453500_ciaf009-B3","author":"Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto"},{"key":"2025060412003453500_ciaf009-B4","author":"ClinVar"},{"key":"2025060412003453500_ciaf009-B5","author":"CFTR2"},{"key":"2025060412003453500_ciaf009-B6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2014correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum Mutat"},{"key":"2025060412003453500_ciaf009-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jmoldx.2015.07.005","article-title":"The spectrum of CFTR variants in nonwhite cystic fibrosis patients: implications for molecular diagnostic testing","volume":"18","author":"Schrijver","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025060412003453500_ciaf009-B8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B9","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1001\/jama.2021.5086","article-title":"Tackling the misconception that cystic fibrosis is a \u201cwhite people's disease\u201d","volume":"325","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"2025060412003453500_ciaf009-B10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/10784535231216461","article-title":"The lived experience of African American persons with cystic fibrosis","volume":"29","author":"Ladores","year":"2023","journal-title":"Creat Nurs"},{"key":"2025060412003453500_ciaf009-B11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0042-1759881","article-title":"Diagnosing cystic fibrosis in adults","volume":"44","author":"Barry","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"key":"2025060412003453500_ciaf009-B14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2025060412003453500_ciaf009-B15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B16","doi-asserted-by":"crossref","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2025060412003453500_ciaf009-B17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025060412003453500_ciaf009-B18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ppul.23715","article-title":"Risk factors for mortality before age 18 years in cystic fibrosis","volume":"52","author":"McColley","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ppul.24377","article-title":"Regional variations in longitudinal pulmonary function: a comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3476(98)70441-X","article-title":"Comparison of the clinical manifestations of cystic fibrosis in black and white patients","volume":"132","author":"Hamosh","year":"1998","journal-title":"J Pediatr"},{"key":"2025060412003453500_ciaf009-B21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MCP.0000000000001019","article-title":"Genetic therapies in cystic fibrosis","volume":"29","author":"Taylor-Cousar","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2025060412003453500_ciaf009-B23","doi-asserted-by":"crossref","first-page":"e0166220","DOI":"10.1371\/journal.pone.0166220","article-title":"Factors associated with worse lung function in cystic fibrosis patients with persistent Staphylococcus aureus","volume":"11","author":"Junge","year":"2016","journal-title":"PLoS One"},{"key":"2025060412003453500_ciaf009-B24","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/ppul.24906","article-title":"Impact at school age of early chronic methicillin-sensitive Staphylococcus aureus infection in children with cystic fibrosis","volume":"55","author":"Galod\u00e9","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"2025060412003453500_ciaf009-B27","doi-asserted-by":"crossref","first-page":"19890","DOI":"10.1073\/pnas.0606756104","article-title":"Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa","volume":"103","author":"Hoffman","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025060412003453500_ciaf009-B28","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1128\/AAC.00742-15","article-title":"Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge","volume":"59","author":"Kriegeskorte","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412003453500_ciaf009-B29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cid\/cit270","article-title":"Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis","volume":"57","author":"Wolter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025060412003453500_ciaf009-B30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S2213-2600(19)30365-0","article-title":"Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study","volume":"7","author":"Wolter","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025060412003453500_ciaf009-B31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/JCM.01510-06","article-title":"Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease","volume":"45","author":"Besier","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2025060412003453500_ciaf009-B32","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1128\/JCM.00361-08","article-title":"Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis","volume":"46","author":"Schneider","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2025060412003453500_ciaf009-B33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic fibrosis foundation pulmonary guideline: pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2025060412003453500_ciaf009-B34","doi-asserted-by":"crossref","first-page":"i73","DOI":"10.1136\/bmjqs-2013-002315","article-title":"Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures","volume":"23 Suppl 1","author":"Savant","year":"2014","journal-title":"BMJ Qual Saf"},{"key":"2025060412003453500_ciaf009-B35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35 Suppl 1","author":"Saiman","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025060412003453500_ciaf009-B36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2023.05.004","article-title":"Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis","volume":"22","author":"Rosenfeld","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcf.2017.10.008","article-title":"Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis","volume":"17","author":"Heltshe","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"key":"2025060412003453500_ciaf009-B39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ppul.1950120306","article-title":"Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis","volume":"12","author":"Henry","year":"1992","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/shorts.2011.011119","article-title":"Health-related quality of life in cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study","volume":"3","author":"Ashish","year":"2012","journal-title":"JRSM Short Rep"},{"key":"2025060412003453500_ciaf009-B42","first-page":"CD001021","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025060412003453500_ciaf009-B43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1513\/AnnalsATS.202003-204OC","article-title":"Clinical outcomes associated with Burkholderia cepacia complex infection in patients with cystic fibrosis","volume":"17","author":"Somayaji","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2025060412003453500_ciaf009-B44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1513\/AnnalsATS.201408-395OC","article-title":"Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada: 30 years\u2019 experience","volume":"12","author":"Zlosnik","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2025060412003453500_ciaf009-B45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrmicro1085","article-title":"The multifarious, multireplicon Burkholderia cepacia complex","volume":"3","author":"Mahenthiralingam","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"2025060412003453500_ciaf009-B46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3476(84)80993-2","article-title":"Pseudomonas cepacia infection in cystic fibrosis: an emerging problem","volume":"104","author":"Isles","year":"1984","journal-title":"J Pediatr"},{"key":"2025060412003453500_ciaf009-B47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2008.02186.x","article-title":"Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex","volume":"8","author":"Alexander","year":"2008","journal-title":"Am J Transplant"},{"key":"2025060412003453500_ciaf009-B48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13693780802524506","article-title":"Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases","volume":"47","author":"Rodriguez-Tudela","year":"2009","journal-title":"Med Mycol"},{"key":"2025060412003453500_ciaf009-B49","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ccm.2023.06.008","article-title":"Cystic fibrosis-related nontuberculous mycobacterial pulmonary disease","volume":"44","author":"Baird","year":"2023","journal-title":"Clin Chest Med"},{"key":"2025060412003453500_ciaf009-B50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/apm.12903","article-title":"The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis","volume":"126","author":"Ravnholt","year":"2018","journal-title":"APMIS"},{"key":"2025060412003453500_ciaf009-B51","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.3390\/ijms20235868","article-title":"Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients","volume":"20","author":"Degiacomi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025060412003453500_ciaf009-B52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jmri.29041","article-title":"Longitudinal evaluation of bronchial changes in cystic fibrosis patients undergoing elexacaftor\/tezacaftor\/ivacaftor therapy using lung MRI with ultrashort echo-times","volume":"60","author":"David","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"2025060412003453500_ciaf009-B54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2014a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B55","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2025060412003453500_ciaf009-B56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B57","author":"Clinical Trial Finder"},{"key":"2025060412003453500_ciaf009-B58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B59","doi-asserted-by":"crossref","first-page":"1800238","DOI":"10.1183\/13993003.00238-2018","article-title":"The clinical significance of oropharyngeal cultures in young children with cystic fibrosis","volume":"51","author":"Breuer","year":"2018","journal-title":"Eur Respir J"},{"key":"2025060412003453500_ciaf009-B60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum Induction trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025060412003453500_ciaf009-B61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fped.2018.00403","article-title":"Respiratory bacterial culture sampling in expectorating and non-expectorating patients with cystic fibrosis","volume":"6","author":"Eyns","year":"2018","journal-title":"Front Pediatr"},{"key":"2025060412003453500_ciaf009-B62","doi-asserted-by":"crossref","first-page":"00249-2021","DOI":"10.1183\/23120541.00249-2021","article-title":"Impact of the SARS-CoV-2 pandemic on cystic fibrosis centres and care: survey results from US centres","volume":"7","author":"Muhlebach","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025060412003453500_ciaf009-B63","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/ppul.25421","article-title":"Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis","volume":"56","author":"Lenhart-Pendergrass","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2025060412003453500_ciaf009-B64","doi-asserted-by":"crossref","first-page":"e0021521","DOI":"10.1128\/cmr.00215-21","article-title":"Practical guidance for clinical microbiology laboratories: updated guidance for processing respiratory tract samples from people with cystic fibrosis","volume":"37","author":"Saiman","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2025060412003453500_ciaf009-B65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"2025060412003453500_ciaf009-B66","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jcf.2016.09.002","article-title":"Continuous alternating inhaled antibiotic therapy in CF: a single center retrospective analysis","volume":"15","author":"Van de Kerkhove","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B67","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"2025060412003453500_ciaf009-B68","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"2025060412003453500_ciaf009-B69","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-575","DOI":"10.12688\/f1000research.13926.1","article-title":"Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations","volume":"7","author":"Skolnik","year":"2018","journal-title":"F1000Res"},{"key":"2025060412003453500_ciaf009-B70","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2025060412003453500_ciaf009-B71","doi-asserted-by":"crossref","first-page":"e20162642","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"key":"2025060412003453500_ciaf009-B72","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jocn.14646","article-title":"\u201cThrust out of normality\u201d\u2014how adults living with cystic fibrosis experience pulmonary exacerbations: a qualitative study","volume":"28","author":"Schmid-Mohler","year":"2019","journal-title":"J Clin Nurs"},{"key":"2025060412003453500_ciaf009-B73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2025060412003453500_ciaf009-B74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2023.08.007","article-title":"Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: the design of the PREDICT study","volume":"23","author":"Martiniano","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B75","author":"National Jewish Health"},{"key":"2025060412003453500_ciaf009-B76","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"2025060412003453500_ciaf009-B77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B78","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/jpids\/piac071","article-title":"Antimicrobial stewardship in cystic fibrosis","volume":"11","author":"Lloyd","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025060412003453500_ciaf009-B79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcf.2020.02.012","article-title":"Finding the relevance of antimicrobial stewardship for cystic fibrosis","volume":"19","author":"Cogen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B80","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2012.12.006","article-title":"Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients","volume":"12","author":"Waters","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B81","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2021.11.010","article-title":"Preferred health outcome states following treatment for pulmonary exacerbations of cystic fibrosis","volume":"21","author":"McLeod","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025060412003453500_ciaf009-B82","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A pilot randomized clinical trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","volume":"20","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2025060412003453500_ciaf009-B83","author":"Chris Goss"},{"key":"2025060412003453500_ciaf009-B84","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/147.3.559","article-title":"Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo","volume":"147","author":"McLaughlin","year":"1983","journal-title":"J Infect Dis"},{"key":"2025060412003453500_ciaf009-B85","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jcf.2024.03.004","article-title":"Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/e65\/63435959\/ciaf009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/e65\/63435959\/ciaf009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:00:53Z","timestamp":1749052853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/5\/e65\/8156727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,4]]},"published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf009","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2025,5,15]]}}}